Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026

Haemonetics (NYSE: HAE) will release first-quarter fiscal 2027 results at 6:00 am ET on Thursday, Aug. 6, 2026, followed by an investor/analyst call at 8:00 am ET. A live webcast and a one-year replay will be available via the company’s investor relations site.

Analysis

This is a calendar-only event, so the right way to view it is as an implied-volatility and expectations checkpoint rather than a fresh fundamental signal. For HAE, the stock’s near-term tape will likely be driven more by whether investors are positioned for margin recovery and volume normalization than by the print itself; that makes the setup asymmetric if the company merely meets already-embedded expectations.

The main second-order issue is that HAE’s mix gives it leverage to procedural demand and plasma collection utilization, so any commentary on throughput, donor economics, or customer capital discipline can matter more than headline EPS. A clean update would support not just HAE but also higher-quality medtech names with recurring consumables exposure; a weak one would pressure the entire "tools used to enable procedure volume" subgroup because it suggests the recovery is uneven and pricing power is limited.

Consensus may be underestimating how quickly a small/mid-cap medtech can re-rate on a guide reset—both directions. If management raises full-year confidence, the move can compound over 1-3 months as sell-side models catch up; if they hedge even modestly, the stock can de-rate faster than fundamentals justify because liquidity is thin and investors tend to extrapolate one quarter into the next. The key falsifier is not the earnings date, but whether management confirms or cuts the FY27 operating margin and volume bridge.

Key Decisions for Investors

• No pre-earnings directional trade in HAE; wait for the Aug. 6 print and the first 24-48 hours of sell-side revisions before taking risk.
• If HAE gaps down 8-10% on in-line results but guidance is intact, consider a tactical long for a 1-3 month mean-reversion trade; invalidate if FY27 margin or volume assumptions are cut.
• If commentary signals slower volume recovery or weaker customer capex, use a post-call rally to initiate a short HAE / long XLV pair for 1-2 months; target 10-15% relative downside if the market prices in a reset.
• Set an alert for any change in management language around collection volumes, donor incentives, or procedure demand; those are the real catalysts, not the release timing.